Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, discusses regimens on the horizon in mantle cell lymphoma (MCL). Upcoming treatment strategies include CAR T-cell therapies, such as lisocabtagene maraleucel, bispecific CAR T-cells targeting CD19 and CD20, as well as combinations with CAR-T and Bruton’s tyrosine kinase (BTK) inhibitors. Additionally, pirtobrutinib, a non-covalent BTK inhibitor, has shown promising results in patients with relapsed/refractory MCL. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.